Design and synthesis of novel 5-phenyl-N-piperidine ethanone containing 4,5-dihydropyrazole derivatives as potential antitumor agents

European Journal of Medicinal Chemistry

Volumn 51, Issue , 2012, Pages 294-299

  Liu, Xin Hua ^a,b   Li, Jun ^a   Shi, Jing Bo ^a   Song, Bao An ^b   Qi, Xing Bao ^c  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b GUIZHOU UNIVERSITY   (China)

^c CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

4,5 Dihydropyrazole; Antitumor agents; Piperidine; Synthesis

Indexed keywords

1 [2 [5 (2 HYDROXYPHENYL) 3 METHYL 4,5 DIHYDROPYRAZOL 1 YL] 2 OXOETHYL]PIPERIDINE 4 CARBOXAMIDE; 1 [5 (2 HYDROXYPHENYL) 3 METHYL 4,5 DIHYDROPYRAZOL 1 YL] 2 (4 METHYLPIPERIDIN 1 YL)ETHANONE; 3 [1 [2 (2 ETHYLPIPERIDIN 1 YL)ACETYL] 3 PHENYL 4,5 DIHYDRO 1H PYRAZOL 5 YL] 2H CHROMEN 2 ONE; 3 [1 [2 (4 METHYLPIPERIDIN 1 YL)ACETYL] 3 PHENYL 4,5 DIHYDRO 1H PYRAZOL 5 YL] 2H CHROMEN 2 ONE; ANTINEOPLASTIC AGENT; ASPARTIC ACID; BENZENE DERIVATIVE; ETHIDIUM BROMIDE; FLUOROURACIL; GLUTAMINE; LYSINE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; TELOMERASE; TELOMERASE INHIBITOR; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOASSAY; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; HYDROGEN BOND; IC 50; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR INTERACTION; MOLECULAR MODEL; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHEMISTRY TECHNIQUES, SYNTHETIC; DRUG DESIGN; ETHANE; HUMANS; MODELS, MOLECULAR; PIPERIDINES; PROTEIN CONFORMATION; PYRAZOLES; TELOMERASE;

EID: 84862803838     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.02.040     Document Type: Article

References (14)

1. W.E. Wright, and J.W. Shay Curr. Opin. Genet. Dev. 11 2001 98 103
2. A.G. Bodnar, M. Ouellette, M. Frolkis, S.E. Holt, C.P. Chiu, G.B. Morin, C.B. Harley, J.W. Shay, S. Lichtsteiner, and W.E. Wright Science 279 1998 349 352
3. J.G. Andrew, P.S. Anthony, and S. Emmanuel Nature 455 2008 633 636
4. F. Hayat, A. Salahuddin, S. Umar, and A. Azam Eur. J. Med. Chem. 45 2010 4669 4675
5. K.S. Girisha, B. Kalluraya, and N. Vijaya Eur. J. Med. Chem. 45 2010 4640 4644
6. X.H. Liu, B.F. Ruan, J. Li, B.A. Song, H.L. Zhu, P.S. Bhadury, and J. Zhao Mini-Rev. Med. Chem. 11 2011 771 821
7. M.L. Neuhouser Nutr. Cancer 50 2004 1 7
8. L.W. Min Cancer Treat. Rev. 35 2009 57 68
9. X.H. Liu, B.F. Ruan, J.X. Liu, B.A. Song, L.H. Jing, J. Li, Y. Yang, H.L. Zhu, and X.B. Qi Bioorg. Med. Chem. Lett. 21 2011 2916 2920
10. X.H. Liu, H.F. Liu, J. Chen, Y. Yang, B.A. Song, L.S. Bai, J.X. Liu, H.L. Zhu, and X.B. Qi Bioorg. Med. Chem. Lett. 20 2010 5705 5708
11. E. Pascolo, C. Wenz, J. Lingner, N. Hauel, H. Priepke, I. Kauffmann, P. Garin-Chesa, W.J. Rettig, K. Damm, and A. Schnapp J. Biol. Chem. 277 2002 15566 15572
12. Y. Peng, I.S. Mian, and N.F. Lue Mol. Cell 7 2001 1201 1211
13. X.H. Liu, J. Li, F.R. Wu, B.A. Song, P.S. Bhadury, and L. Shi Med. Chem. 7 2011 605 610
14. G.M. Sheldrick SHELXTL-97, Program for Crystal Structure Solution and Refinement 1997 University of Göttingen Göttingen, Germany